JNJ

168.06

-0.1%↓

NVS

117.08

+0.01%↑

ABT

128.75

+1.12%↑

MDT

92.12

-0.59%↓

ELV.US

291.02

-0.12%↓

JNJ

168.06

-0.1%↓

NVS

117.08

+0.01%↑

ABT

128.75

+1.12%↑

MDT

92.12

-0.59%↓

ELV.US

291.02

-0.12%↓

JNJ

168.06

-0.1%↓

NVS

117.08

+0.01%↑

ABT

128.75

+1.12%↑

MDT

92.12

-0.59%↓

ELV.US

291.02

-0.12%↓

JNJ

168.06

-0.1%↓

NVS

117.08

+0.01%↑

ABT

128.75

+1.12%↑

MDT

92.12

-0.59%↓

ELV.US

291.02

-0.12%↓

JNJ

168.06

-0.1%↓

NVS

117.08

+0.01%↑

ABT

128.75

+1.12%↑

MDT

92.12

-0.59%↓

ELV.US

291.02

-0.12%↓

Search

Xenon Pharmaceuticals Inc

Open

SectorGezondheidszorg

31.4 1.85

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

30.36

Max

31.65

Belangrijke statistieken

By Trading Economics

Inkomsten

638K

-65M

Verkoop

7.5M

7.5M

Winstmarge

-867.293

Werknemers

316

EBITDA

4.1M

-73M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+79.66% upside

Dividenden

By Dow Jones

Volgende Winsten

7 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-369M

2.4B

Vorige openingsprijs

29.55

Vorige sluitingsprijs

31.4

Nieuwssentiment

By Acuity

75%

25%

354 / 375 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

Xenon Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

29 jul 2025, 23:57 UTC

Acquisities, Fusies, Overnames

EQT: To Spend Y407.82B for Tender Offer

29 jul 2025, 23:56 UTC

Acquisities, Fusies, Overnames

EQT: Tender Offer Price Is Y5,700 a Share

29 jul 2025, 23:54 UTC

Acquisities, Fusies, Overnames

EQT To Start Tender Offer for Fujitec

29 jul 2025, 23:50 UTC

Marktinformatie

Nikkei May Fall Amid Uncertainty Over Earnings, Domestic Politics -- Market Talk

29 jul 2025, 23:36 UTC

Marktinformatie

Gold Steady Ahead of FOMC Decision -- Market Talk

29 jul 2025, 22:57 UTC

Marktinformatie

Perseus May Step Up Capital Management at FY 2025 Result -- Market Talk

29 jul 2025, 22:50 UTC

Marktinformatie

Mondelez Warns of Price Increases in North America -- Market Talk

29 jul 2025, 22:44 UTC

Acquisities, Fusies, Overnames

St Barbara: Potential Divestment of Nova Scotia Ops to be Weighed in 1Q FY26

29 jul 2025, 22:41 UTC

Acquisities, Fusies, Overnames

St Barbara FY25 All-in Sustaining Cost A$4,582/Oz

29 jul 2025, 22:41 UTC

Acquisities, Fusies, Overnames

St Barbara 4Q All-in Sustaining Cost A$4,613/Oz

29 jul 2025, 22:35 UTC

Winsten

IGO Maintains Nova Life of Mine Production Guidance

29 jul 2025, 22:35 UTC

Winsten

IGO Expects FY 2026 Greenbushes Output of 1.50 Million-1.65 Million Tons

29 jul 2025, 22:35 UTC

Winsten

IGO Expects FY 2026 Greenbushes Cash Costs of A$310-A$360/Ton

29 jul 2025, 22:34 UTC

Winsten

IGO Expects Train 1 of Kwinana Refinery to Be Fully Impaired

29 jul 2025, 22:34 UTC

Winsten

IGO Expects to Impair Kwinana Refinery Assets by A$70 Million-A$90 Million

29 jul 2025, 22:34 UTC

Marktinformatie
Winsten

Mondelez Snack Demand Holding Up Better in Europe Than U.S. -- Market Talk

29 jul 2025, 22:33 UTC

Winsten

IGO Had A$279.7 Million of Cash at End-June

29 jul 2025, 22:33 UTC

Winsten

IGO 4Q Underlying Free Cash A$2.4 Million

29 jul 2025, 22:33 UTC

Winsten

IGO FY Sales Revenue A$512.5 Million

29 jul 2025, 22:33 UTC

Winsten

IGO 4Q Sales Revenue A$126.9 Million, Up 15% on 3Q

29 jul 2025, 22:32 UTC

Winsten

IGO FY Nickel Production 17,173 Tons

29 jul 2025, 22:32 UTC

Winsten

IGO 4Q Nickel Production 5,107 Tons, Up 22% on 3Q

29 jul 2025, 22:32 UTC

Winsten

IGO 4Q Lithium Hydroxide Production 2,126 Tons, Up 36% on 3Q

29 jul 2025, 22:31 UTC

Marktinformatie
Winsten

Global Equities Roundup: Market Talk

29 jul 2025, 22:31 UTC

Marktinformatie
Winsten

Mondelez Sees Consumers Trading Down, Buying in Bulk -- Market Talk

29 jul 2025, 22:31 UTC

Winsten

IGO 4Q Spodumene Cash Cost A$366/Ton, Up 7% on 3Q

29 jul 2025, 22:31 UTC

Winsten

IGO FY Spodumene Production 1.48 Million Tons

29 jul 2025, 22:30 UTC

Winsten

IGO 4Q Spodumene Production 340,000 Tons, Flat on 3Q

29 jul 2025, 22:30 UTC

Winsten

IGO 4Q Underlying Ebitda A$62 Million

29 jul 2025, 22:22 UTC

Winsten

Starbucks Abandons Mobile Order, Pickup-Only Stores -- WSJ

Peer Vergelijking

Prijswijziging

Xenon Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

79.66% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 55.64 USD  79.66%

Hoogste 65 USD

Laagste 47 USD

Gebaseerd op 14 Wall Street-analisten die 12-maands prijsdoelen bieden voor Xenon Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

14 ratings

14

Buy

0

Hold

0

Sell

Technische score

By Trading Central

34.81 / 38.24Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Neutral Evidence

Sentiment

By Acuity

354 / 375 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.